vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and SOLAREDGE TECHNOLOGIES, INC. (SEDG). Click either name above to swap in a different company.
SOLAREDGE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($335.4M vs $284.0M, roughly 1.2× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -39.4%, a 135.7% gap on every dollar of revenue. On growth, SOLAREDGE TECHNOLOGIES, INC. posted the faster year-over-year revenue change (70.9% vs 9.4%). Over the past eight quarters, SOLAREDGE TECHNOLOGIES, INC.'s revenue compounded faster (28.1% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
SolarEdge Technologies, Inc. is an Israeli company that developed a DC optimized inverter system.
ACAD vs SEDG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $335.4M |
| Net Profit | $273.6M | $-132.1M |
| Gross Margin | 90.8% | 22.2% |
| Operating Margin | 6.1% | -14.4% |
| Net Margin | 96.3% | -39.4% |
| Revenue YoY | 9.4% | 70.9% |
| Net Profit YoY | 90.3% | 54.0% |
| EPS (diluted) | $1.61 | $-2.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $335.4M | ||
| Q3 25 | $278.6M | $340.2M | ||
| Q2 25 | $264.6M | $289.4M | ||
| Q1 25 | $244.3M | $219.5M | ||
| Q4 24 | $259.6M | $196.2M | ||
| Q3 24 | $250.4M | $235.4M | ||
| Q2 24 | $242.0M | $265.4M | ||
| Q1 24 | $205.8M | $204.4M |
| Q4 25 | $273.6M | $-132.1M | ||
| Q3 25 | $71.8M | $-50.1M | ||
| Q2 25 | $26.7M | $-124.7M | ||
| Q1 25 | $19.0M | $-98.5M | ||
| Q4 24 | $143.7M | $-287.4M | ||
| Q3 24 | $32.8M | $-1.2B | ||
| Q2 24 | $33.4M | $-130.8M | ||
| Q1 24 | $16.6M | $-157.3M |
| Q4 25 | 90.8% | 22.2% | ||
| Q3 25 | 92.2% | 21.2% | ||
| Q2 25 | 92.2% | 11.1% | ||
| Q1 25 | 91.7% | 8.0% | ||
| Q4 24 | 91.6% | -57.2% | ||
| Q3 24 | 92.5% | -309.1% | ||
| Q2 24 | 92.5% | -4.1% | ||
| Q1 24 | 88.8% | -12.8% |
| Q4 25 | 6.1% | -14.4% | ||
| Q3 25 | 12.8% | -10.3% | ||
| Q2 25 | 12.2% | -39.9% | ||
| Q1 25 | 7.9% | -46.8% | ||
| Q4 24 | 59.1% | -134.4% | ||
| Q3 24 | 12.6% | -471.8% | ||
| Q2 24 | 12.6% | -60.4% | ||
| Q1 24 | 7.4% | -85.0% |
| Q4 25 | 96.3% | -39.4% | ||
| Q3 25 | 25.8% | -14.7% | ||
| Q2 25 | 10.1% | -43.1% | ||
| Q1 25 | 7.8% | -44.9% | ||
| Q4 24 | 55.4% | -146.5% | ||
| Q3 24 | 13.1% | -522.8% | ||
| Q2 24 | 13.8% | -49.3% | ||
| Q1 24 | 8.0% | -77.0% |
| Q4 25 | $1.61 | $-2.21 | ||
| Q3 25 | $0.42 | $-0.84 | ||
| Q2 25 | $0.16 | $-2.13 | ||
| Q1 25 | $0.11 | $-1.70 | ||
| Q4 24 | $0.86 | $-5.00 | ||
| Q3 24 | $0.20 | $-21.58 | ||
| Q2 24 | $0.20 | $-2.31 | ||
| Q1 24 | $0.10 | $-2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $493.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $427.5M |
| Total Assets | $1.6B | $2.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $493.2M | ||
| Q3 25 | $258.0M | $498.6M | ||
| Q2 25 | $253.6M | $758.0M | ||
| Q1 25 | $217.7M | $651.6M | ||
| Q4 24 | $319.6M | $585.9M | ||
| Q3 24 | $155.1M | $678.8M | ||
| Q2 24 | $177.1M | $689.8M | ||
| Q1 24 | $204.7M | $680.6M |
| Q4 25 | $1.2B | $427.5M | ||
| Q3 25 | $917.3M | $479.8M | ||
| Q2 25 | $822.4M | $513.2M | ||
| Q1 25 | $765.2M | $594.2M | ||
| Q4 24 | $732.8M | $658.3M | ||
| Q3 24 | $577.2M | $930.9M | ||
| Q2 24 | $516.7M | $2.1B | ||
| Q1 24 | $464.0M | $2.2B |
| Q4 25 | $1.6B | $2.2B | ||
| Q3 25 | $1.3B | $2.2B | ||
| Q2 25 | $1.2B | $2.5B | ||
| Q1 25 | $1.1B | $2.5B | ||
| Q4 24 | $1.2B | $2.6B | ||
| Q3 24 | $976.9M | $2.8B | ||
| Q2 24 | $914.1M | $3.9B | ||
| Q1 24 | $855.1M | $4.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $52.6M |
| Free Cash FlowOCF − Capex | — | $43.3M |
| FCF MarginFCF / Revenue | — | 12.9% |
| Capex IntensityCapex / Revenue | — | 2.8% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $80.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $52.6M | ||
| Q3 25 | $74.3M | $25.6M | ||
| Q2 25 | $64.0M | $-7.8M | ||
| Q1 25 | $20.3M | $33.8M | ||
| Q4 24 | $40.4M | $37.8M | ||
| Q3 24 | $63.2M | $-89.3M | ||
| Q2 24 | $25.0M | $-44.8M | ||
| Q1 24 | $29.1M | $-217.0M |
| Q4 25 | — | $43.3M | ||
| Q3 25 | $73.9M | $22.8M | ||
| Q2 25 | — | $-9.1M | ||
| Q1 25 | — | $23.7M | ||
| Q4 24 | — | $25.5M | ||
| Q3 24 | $63.2M | $-136.7M | ||
| Q2 24 | — | $-67.0M | ||
| Q1 24 | — | $-243.4M |
| Q4 25 | — | 12.9% | ||
| Q3 25 | 26.5% | 6.7% | ||
| Q2 25 | — | -3.1% | ||
| Q1 25 | — | 10.8% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 25.2% | -58.1% | ||
| Q2 24 | — | -25.2% | ||
| Q1 24 | — | -119.1% |
| Q4 25 | — | 2.8% | ||
| Q3 25 | 0.1% | 0.8% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 4.6% | ||
| Q4 24 | — | 6.2% | ||
| Q3 24 | 0.0% | 20.1% | ||
| Q2 24 | — | 8.4% | ||
| Q1 24 | — | 12.9% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
SEDG
| Other | $197.7M | 59% |
| Europe Except Netherlands | $99.4M | 30% |
| Others | $38.2M | 11% |
